Snap-8
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Extended version of Argireline with improved efficacy.
Reported benefits
Stronger wrinkle reduction than Argireline
Protocols & dosing
Typical dosage: Topical 5-10% (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Snap-8 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Very safe topically
References
No external sources have been catalogued for this article yet.
Related peptides
- Argireline (Acetyl Hexapeptide-8) — Botox-like peptide
- Copper Peptide GHK-Cu — Multi-functional skin peptide
- Copper Peptides — Skin regeneration
- GHK-Cu — Skin health, anti-aging, wound healing
- Hexapeptide-11 — Cell renewal peptide
- Matrixyl (Palmitoyl Pentapeptide) — Anti-aging skincare
Categories: Cosmetic & Skin